Sökning: WFRF:(Storey Robert F.)
> (2010-2014)
> (2010)
> Kilhamn Jan >
Ticagrelor Versus C...
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
-
Steg, Philippe Gabriel (författare)
-
- James, Stefan (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
Harrington, Robert A. (författare)
-
visa fler...
-
Ardissino, Diego (författare)
-
Becker, Richard C. (författare)
-
Cannon, Christopher P. (författare)
-
Emanuelsson, Håkan (författare)
-
Finkelstein, Ariel (författare)
-
Husted, Steen (författare)
-
Katus, Hugo (författare)
-
Kilhamn, Jan (författare)
-
- Olofsson, Sylvia (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
Storey, Robert F. (författare)
-
Weaver, Douglas (författare)
-
- Wallentin, Lars (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
visa färre...
-
(creator_code:org_t)
- 2010
- 2010
- Engelska.
-
Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 122:21, s. 2131-2141
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background-Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervention. Methods and Result-Platelet Inhibition and Patient Outcomes (PLATO), a randomized, double-blind trial, compared ticagrelor with clopidogrel for the prevention of vascular events in 18 624 ACS patients. This report concerns the 7544 ACS patients with STE or left bundle-branch block allocated to either ticagrelor 180-mg loading dose followed by 90 mg twice daily or clopidogrel 300-mg loading dose (with provision for 300 mg clopidogrel at percutaneous coronary intervention) followed by 75 mg daily for 6 to 12 months. The reduction of the primary end point (myocardial infarction, stroke, or cardiovascular death) with ticagrelor versus clopidogrel (10.8% versus 9.4%; hazard ratio [HR], 0.87; 95% confidence interval, 0.75 to 1.01; P=0.07) was consistent with the overall PLATO results. There was no interaction between presentation with STE/left bundle-branch block and randomized treatment (interaction P=0.29). Ticagrelor reduced several secondary end points, including myocardial infarction alone (HR, 0.80; P=0.03), total mortality (HR, 0.82; P=0.05), and definite stent thrombosis (HR, 0.66; P=0.03). The risk of stroke, low in both groups, was higher with ticagrelor (1.7% versus 1.0%; HR, 1.63; 95% confidence interval, 1.07 to 2.48; P=0.02). Ticagrelor did not affect major bleeding (HR, 0.98; P=0.76). Conclusion-In patients with STE-ACS and planned primary percutaneous coronary intervention, the effects of ticagrelor were consistent with those observed in the overall PLATO trial.
Nyckelord
- acute coronary syndrome
- hemorrhage
- myocardial infarction
- platelets
- thrombosis
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Steg, Philippe G ...
-
James, Stefan
-
Harrington, Robe ...
-
Ardissino, Diego
-
Becker, Richard ...
-
Cannon, Christop ...
-
visa fler...
-
Emanuelsson, Håk ...
-
Finkelstein, Ari ...
-
Husted, Steen
-
Katus, Hugo
-
Kilhamn, Jan
-
Olofsson, Sylvia
-
Storey, Robert F ...
-
Weaver, Douglas
-
Wallentin, Lars
-
visa färre...
- Artiklar i publikationen
-
Circulation
- Av lärosätet
-
Uppsala universitet